Advisory Board | Kisaco Research

Global Advisory Board

Author:

Tim Bettington

Executive Vice President, Corporate Strategy & Market Development
Elanco

Tim Bettington

Executive Vice President, Corporate Strategy & Market Development
Elanco

Author:

Jamie Brannan

Executive Vice President and Chief Commercial Officer
Zoetis

Jamie Brannan

Executive Vice President and Chief Commercial Officer
Zoetis

Author:

Paul Casady

Senior Consultant
Brakke Consulting

Paul Casady

Senior Consultant
Brakke Consulting

Author:

Claire Fowler

SVP Head of Global Strategic Marketing Animal Health,
Boehringer Ingelheim

After completing a degree in Veterinary Medicine at Cambridge University in 2002, her first professional experience was working in clinical veterinary practice before joining Boehringer Ingelheim in 2005. She subsequently completed an MBA at London Business School.

 

In Boehringer Ingelheim she has held positions at a local, regional and global level across business management, marketing and technical functions, mainly in Animal Health. This includes senior leadership roles such as the responsibility for the Boehringer Ingelheim Italian animal health subsidiary, and most recently for the overall commercial performance of the region encompassing Europe and Canada.  She also spent some time in Consumer Health Care as Category lead in global marketing.

 

Claire was appointed Head of Global Strategic Marketing in January 2025 and became a member of the Executive Committee of the Animal Health Business Unit at Boehringer.

Claire Fowler

SVP Head of Global Strategic Marketing Animal Health,
Boehringer Ingelheim

After completing a degree in Veterinary Medicine at Cambridge University in 2002, her first professional experience was working in clinical veterinary practice before joining Boehringer Ingelheim in 2005. She subsequently completed an MBA at London Business School.

 

In Boehringer Ingelheim she has held positions at a local, regional and global level across business management, marketing and technical functions, mainly in Animal Health. This includes senior leadership roles such as the responsibility for the Boehringer Ingelheim Italian animal health subsidiary, and most recently for the overall commercial performance of the region encompassing Europe and Canada.  She also spent some time in Consumer Health Care as Category lead in global marketing.

 

Claire was appointed Head of Global Strategic Marketing in January 2025 and became a member of the Executive Committee of the Animal Health Business Unit at Boehringer.

Author:

Rob Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD Animal Health

Rob Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD Animal Health

Author:

Julia Loew

Chief Commercial Officer
MWI Animal Health

Julia Loew

Chief Commercial Officer
MWI Animal Health

Author:

Alan Mackay

Managing Partner and Founder
GHO Capital

Alan Mackay

Managing Partner and Founder
GHO Capital

Author:

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Author:

Aaron Schacht

CEO
BiomEdit

Aaron Schacht

CEO
BiomEdit

Author:

Beatrice Vos, PhD

Partner
Stonehaven Cozmix Group (and CEO @ SC Transactions AG)

Beatrice Vos, PhD

Partner
Stonehaven Cozmix Group (and CEO @ SC Transactions AG)

Author:

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Innovation Advisory Board

Author:

Aaron Schacht

CEO
BiomEdit

Aaron Schacht

CEO
BiomEdit

Author:

Fabian Kausche

Deputy General for Research & Innovation / Board Member
ILRI / GALVmed, FidoCure, PetFlavours, RVC, Novobind, Sequent, Rejuvenate Bio

Fabian Kausche

Deputy General for Research & Innovation / Board Member
ILRI / GALVmed, FidoCure, PetFlavours, RVC, Novobind, Sequent, Rejuvenate Bio

Author:

Julia Loew

Chief Commercial Officer
MWI Animal Health

Julia Loew

Chief Commercial Officer
MWI Animal Health

Author:

Joachim Hasenmaier

Supervisory Board Member
ECO Animal Health, Invetx, Phagelux

Joachim Hasenmaier

Supervisory Board Member
ECO Animal Health, Invetx, Phagelux

Author:

Alexander Petersen

Managing Director & Animal Health Lead
Corporate Finance Associates




Alexander Petersen

Managing Director & Animal Health Lead
Corporate Finance Associates




Author:

Roman Makovitskiy

Managing Director & Global Head of Animal Health Investment Banking
BofA Securities

Roman Makovitskiy

Managing Director & Global Head of Animal Health Investment Banking
BofA Securities

Author:

Marcus Remmer

Partner
Novo Holdings

Marcus Remmer

Partner
Novo Holdings

Author:

Linda Black

CEO
Gallant Therapeutics

Linda Black

CEO
Gallant Therapeutics

Author:

Dino Dedic, CFA

Senior Managing Director
Guggenheim Partners

Dino Dedic, CFA

Senior Managing Director
Guggenheim Partners

Author:

Christie Chavis

Chief Commercial Officer
Datamars

Christie Chavis

Chief Commercial Officer
Datamars

Author:

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Author:

Greg Blair

Vice President of Business Development
Zomedica

Greg Blair

Vice President of Business Development
Zomedica